Q3 2023 EPS Estimates for AngioDynamics, Inc. (NASDAQ:ANGO) Reduced by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGOGet Rating) – Stock analysts at Zacks Research decreased their Q3 2023 EPS estimates for shares of AngioDynamics in a research report issued to clients and investors on Tuesday, January 17th. Zacks Research analyst D. Dey now expects that the medical instruments supplier will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for AngioDynamics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for AngioDynamics’ Q3 2024 earnings at $0.01 EPS, Q4 2024 earnings at $0.06 EPS, FY2024 earnings at $0.10 EPS, Q1 2025 earnings at $0.03 EPS and Q2 2025 earnings at $0.06 EPS.

Several other brokerages have also recently weighed in on ANGO. StockNews.com began coverage on shares of AngioDynamics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Raymond James lowered their price target on shares of AngioDynamics from $25.00 to $22.00 and set a “strong-buy” rating for the company in a research report on Friday, January 6th.

AngioDynamics Price Performance

Shares of ANGO opened at $13.32 on Friday. The company has a 50 day moving average price of $13.34 and a 200-day moving average price of $17.49. AngioDynamics has a fifty-two week low of $11.71 and a fifty-two week high of $24.87. The stock has a market capitalization of $521.26 million, a PE ratio of -16.05 and a beta of 0.66. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.30 and a current ratio of 2.16.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its stake in shares of AngioDynamics by 0.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 166,645 shares of the medical instruments supplier’s stock worth $3,409,000 after acquiring an additional 1,560 shares in the last quarter. Bridgewater Associates LP raised its stake in shares of AngioDynamics by 10.1% during the 2nd quarter. Bridgewater Associates LP now owns 59,819 shares of the medical instruments supplier’s stock worth $1,157,000 after acquiring an additional 5,467 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of AngioDynamics by 10.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,400,992 shares of the medical instruments supplier’s stock worth $27,109,000 after acquiring an additional 134,075 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in shares of AngioDynamics by 9.2% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 314,595 shares of the medical instruments supplier’s stock worth $6,087,000 after acquiring an additional 26,538 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in shares of AngioDynamics by 7.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 51,879 shares of the medical instruments supplier’s stock worth $1,004,000 after acquiring an additional 3,441 shares in the last quarter. Institutional investors own 94.94% of the company’s stock.

About AngioDynamics

(Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Featured Articles

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.